We included studies with several inclusion criteria, including (1) randomized clinical trials, (2) studying a population of T2DM at any age, (3) using IDegAsp as an intervention or independent variable, (4) using another insulin as a controlled variable, (5) analyzing the outcome of IDegAsp use in T2DM, such as HbA1C changes and hypoglycemia events that compared with the control insulin, and (6) written in English. The gene discussed is INS; the disease is type 2 diabetes mellitus.